Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 8;5:JGO.18.00216. doi: 10.1200/JGO.18.00216

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 2 — Survival comparison of older versus younger patients in different patient groups: (A) Kaplan-Meier curve of all patients divided into two age groups: 62 patients younger than age 40 years (n = 28 censored) and 124 patients older than age 60 years (n = 44 censored). Median survival for the younger group was 34 months and 21.2 months for the older group. P = .19. (B) Kaplan-Meier curve of all patients divided into four age groups: 16 patients younger than age 40 years (n = 9 censored), 46 patients age 41-50 years (n = 19 censored), 82 patients age 60-69 years (n = 32 censored), and 42 patients older than age 70 years (n = 12 censored). Median survival for the youngest group was 59.6 months, 26.1 months for those age 41- 50 years, 25 months for those age 60-69 years, and 17.2 months for the oldest age group. Significance: P = .2. Kaplan-Meier curves of driver mutation–positive patients: (C) Kaplan-Meier curve of epidermal growth factor receptor (EGFR) mutation–positive patients: 14 patients were younger than age 50 years (n = 6 censored) and 22 patients were older than age 60 years (n = 8 censored). Median survival was 33.5 months for younger patients and 22.8 months for older patients. Significance: P = .61. (D) Kaplan-Meier curve of anaplastic lymphoma kinase (ALK) rearrangement–positive patients: eight patients were younger than age 50 years (n = 3 censored) and two patients were older than age 60 years (n = 0 censored). Median survival was 35.5 months for younger patients and 14.4 months for older patients. Significance: P = .3. (E) Patients who developed brain metastases: 24 patients were younger than age 50 years (n = 7 censored) and 31 patients were older than age 60 years (n = 4 censored). Median survival was 24.6 months for younger patients and 18 months for older patients. Significance: P = .4. (F) Patients who did not developed brain metastases: 36 patients were younger than age 50 years (n = 20 censored) and 93 patients were older than age 60 years (n = 40 censored). Median survival was 58.8 months for younger patients and 21.6 months for older patients. Significance: P = 0.